Subscribe - Individual

Subscribe - Biotech Premium (Corporate)


November 3rd, 2023

Chimeric Therapeutics - Four Phase Ib Studies in 2024 Ahead of Partnering Deals

For Chimeric Therapeutics (CHM: $0.029), achieving Phase Ib data from its programs is expected to position the company for licensing deals ahead of registration Phase II studies with CAR-T cell therapies.

CHM 938
May 19th, 2023

Chimeric Therapeutics Opens $6.3 Million Capital Raise

Chimeric Therapeutics (CHM: $0.039) has announced a capital raise for up to $6.3 million, which comprises of a $1.04 million placement to board and management and a $5.25 million SPP.

April 6th, 2023

Chimeric Therapeutics - Viral Vector Manufacturing Achieved

Chimeric Therapeutics (CHM: $0.076) is commercialising cell therapy technologies sourced from three US research institutions to treat a range of poorly addressed cancers. Patients with these diseases had a five-year survival expectation of just 5% - 27%.

May 25th, 2022

Chimeric Antigen Receptor T Cell Therapies

CAR-T therapies currently remain predominantly for use in oncology according to Chimeric Therapeutics CEO and Bioshares Biotech Summit keynote speaker Jennifer Chow.

Cancer therapies commenced largely in the 1940's with chemotherapy, which could be described as bombing the patient with broad acting drugs. This was followed by targeted therapies in the 1990's such as monoclonal antibodies. In the last decade, the major advances have been in immunotherapies, such as checkpoint therapies. These targeted therapies started to improve short-term survival, and then the immunotherapies were found to improve long-term survival.

April 1st, 2022

Chimeric Therapeutics Raises $14 Million in Rights Issue

Chimeric Therapeutics (CHM: $0.14) has raised $14.4 million through a rights issue conducted at $0.17 per share. The company finished last year with $13.4 million in cash following its IPO in January last year when the company raised $35 million at $0.20 per share.

maxresdefault 1
February 14th, 2022

Chimeric Therapeutics Reports Good Data in Second Patient Cohort

Chimeric Therapeutics (CHM: $0.21) has finished dosing the second cohort of three patients in its chlorotoxin CAR-T cell therapy in patients with glioblastoma.